Objective
The main objective of this review is to elucidate topical ganciclovir 0.15% gel in the therapy and prophylaxis of herpetic keratitis.
Human Herpes Virus
HHV-1 is the most commonly encountered virus in herpetic keratitis. The word "herpes" is derived from the Greek word "herpein" or "to creep" because of the characteristic cutaneous eruption. HHV is a doublestranded DNA virus consisting of 12 pentavalent and 150 hexavalent capsomeres measuring 110 nm. The DNA virus is in proteinaceous matrix and has a lipid envelope measuring 220 nm. 4 HHV may affect any of the ocular structures or adnaxae. HHV is a great mimicker of other microbial keratitis cases. Ocular manifestations may include blepharitis, conjunctivitis, keratitis, optic neuritis, uveitis, retinitis, and trabeculitis.
By far the most common manifestation of herpetic disease of the eye is keratitis. The keratitis may be epithelial, stromal, or endothelial. HHV may affect immunocompetent and immunocompromised hosts. The optimal dosage of the antiviral prophylactic agents should be determined.
In patients who undergo PKP for herpetic corneal scars, the rate of recurrences without prophylaxis may be high. Oral antivirals in herpetic keratitis are used for the prevention of HHV recurrences. 15 They are potentially nephrotoxic, the cost is high, they have limited ocular tissue absorption, cannot be used in pregnancy, and cannot be used long-term. 
CNS = central nervous system, HHV = human herpes virus
Topical ganciclovir gel in herpetic keratitis has no ocular surface complications, no hematologic side-effects, and does not reach to toxic levels in the blood stream following topical application, and, therefore, does not lead to nephrotoxicity or bone marrow suppression.
In patients with corneal scars due to HHV infection and undergoing PKP, it is recommended that they are placed on prophylactic topical ganciclovir to prevent recurrences of herpetic keratitis in the corneal graft and subsequent corneal rejection. Several antiviral agents can be ineffective due to resistance of the virus, causing it to recur mainly in immunocompromised patients and sometimes in immunocompetent patients.
Topical Ganciclovir
Ganciclovir inhibits DNA polymerase and interferes with DNA synthesis.
Topical ganciclovir 0.15% gel was evaluated in the treatment of herpetic keratitis. [16] [17] [18] [19] A total of 16 consecutive patients with herpetic keratitis were included in a non-randomized prospective, interventional study. There were 12 male and 4 female patients with herpetic epithelial keratitis (see Figures 1-3 ).
The age range was 26-80 years (mean age: 47 years). Ten cases had dendritic keratitis and six patients had recurrent geographic epithelial keratitis.
Complete resolution of the herpetic keratitis was noted in all patients.
The corneal lesions in 11 (69%) of the 16 patients healed within 7 days, and 5 (31%) patients healed within 3 weeks. 18 There were no ocular side effects from the topical use of ganciclovir noted among the 16 patients. The effect of ganciclovir in the treatment of herpetic epithelial keratitis was compared to acyclovir 3% ointment. Topical ganciclovir and topical acyclovir were equally effective in the therapy of herpetic epithelial keratitis. 17 In our experience, topical use of ganciclovir in adenoviral keratoconjunctivitis has limited efficacy and does not prevent subepithelial corneal opacities following adenoviral keratoconjunctivitis.
Ganciclovir Prophylaxis Following Penetrating Keratoplasty
The topical use of corticosteroids helps in the prevention of corneal graft rejection but at the same time increases the susceptibility of recurrences of herpetic keratitis. The recurrences of herpetic keratitis may lead to corneal graft rejection. We studied the effects of topical ganciclovir 0.15% gel in the prophylaxis of herpetic epithelial keratitis following PKP.
Prophylactic topical ganciclovir may lead to prevention of recurrent herpetic keratitis following PKP for patients with corneal scars secondary to previous herpetic keratitis. 18 Topical ganciclovir appears to be more effective than oral acyclovir in the prevention of recurrences of herpetic keratitis following PKP (Figures 4a, 4b) . 18 Topical ganciclovir in herpetic keratitis is a helpful therapeutic modality for the management of recurrent herpetic epithelial keratitis and in the prophylaxis of patients with herpetic keratitis following PKP ( Figure 5 ).
Topical ganciclovir has no significant systemic absorption, and therefore no hematologic abnormalities are noted. The gel is easy to apply, does not cause blurring or irritation, is well tolerated, and has no toxic effect on the ocular surface. Ganciclovir 0.15% gel has potential role in the prophylaxis of patients with herpetic keratitis undergoing PKP.
The main indication for therapy of recurrent herpetic keratitis with topical ganciclovir 0.15% gel is to relieve the discomfort, prevent sight threatening complications, and prevent recurrences induced by the prolonged use of topical steroids use after PKP.
The Herpetic Eye Disease Study (HDES) 9 was a multicenter, randomized trial which enrolled 703 patients. It focused on the use of oral acyclovir to prevent Cornea US OPHTHALMIC REVIEW herpetic epithelial and stromal keratitis, and determined the recurrence rate following prophylaxis with oral acyclovir. 8 Each patient included in the study had at least one episode of ocular herpes virus in the previous 12 months and no disease activity within the previous 30 days. 9 Patients were assigned to receive either 400 mg acyclovir twice daily or placebo. 9 Patients were examined at day 1, 3, 6, 9, and 12 months after the start of treatment.
Recurrences of ocular herpes in the placebo group was 32% in the 
